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The metabolic impact of the common peroxisome
proliferator-activated receptor gamma isoform 2
(PPARg2) variant Pro12Ala in human populations
has been widely debated. We demonstrate, using
a Pro12Ala knockin model, that on chow diet, Ala/
Ala mice are leaner, have improved insulin sensitivity
and plasma lipid profiles, and have longer lifespans.
Gene-environment interactions played a key role as
high-fat feeding eliminated the beneficial effects of
the Pro12Ala variant on adiposity, plasma lipids,
and insulin sensitivity. The underlying molecular
mechanisms involve changes in cofactor interaction
and adiponectin signaling. Altogether, our results
establish the Pro12Ala variant of Pparg2 as an impor-
tant modulator in metabolic control that strongly de-
pends on the metabolic context.
INTRODUCTION
Peroxisome proliferator-activated receptor gamma (PPARg),
and especially the PPARg2 isoform, is a ligand-dependent nu-
clear receptor highly expressed in adipose tissue, where it coor-
dinates a thrifty phenotype by promoting adipocyte differentia-
tion and triglyceride storage (Auwerx, 1999; Fajas et al., 1997;
Lehrke and Lazar, 2005; Tontonoz et al., 1994b). The metabolic
functions of PPARg also include the coordination of glucose ho-
meostasis and insulin sensitivity (Knouff and Auwerx, 2004).
Consequently, synthetic PPARg agonists such as the thiazolidi-
nediones (TZDs) have proven valuable in the pharmacological
management of type 2 diabetes (T2DM) (Lehmann et al., 1995).
The common Pro12Ala variant of PPARg2 (Ala frequency
920% [Heikkinen et al., 2007]) causes a moderate decrease in
its transcriptional activity and adipogenic potential (Deeb et al.,
1998; Masugi et al., 2000). We previously associated the Pro12
variant with the risk of T2DM (Deeb et al., 1998). Recent meta-
analyses (Florez et al., 2003; Ludovico et al., 2007; To¨njes
et al., 2006) and genome-wide association studies (GWAS) (Sax-88 Cell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc.ena et al., 2007; Scott et al., 2007; Sladek et al., 2007; Steinthors-
dottir et al., 2007; Zeggini et al., 2007) have confirmed our orig-
inal findings. The Ala12 allele has also been associated with
reduced weight gain and improved insulin sensitivity, particularly
in lean subjects (Altshuler et al., 2000; Deeb et al., 1998; Ek et al.,
1999). However, these observations have been challenged, es-
pecially in obese subjects where the Ala allele has been associ-
ated with increased weight gain (Ek et al., 1999). Thus, the
Pro12Ala genotype appears to be sensitive to environmental in-
fluence, such that the Ala allele is beneficial in lean subjects but
could be detrimental when coexisting with obesity.
Genetic association studies are valuable to identify potential
disease genes. Ultimately, however, a mouse model system is
needed to understand the mechanistic impact of such genes
and their variants. We have generated a knockin mouse model
for the PPARg2 Pro12Ala variant to understand the fundamental
physiological and molecular roles of PPARg2 and its Pro12Ala
variant. Our results strengthen the view that the Pro/Pro of
PPARG2 is a risk genotype that adversely affects glucose ho-
meostasis and lifespan. Furthermore, the protective role of the
Ala/Ala genotype depends on the dietary context, suggesting
that the metabolic impact of this mutation is highly dependent
on gene-environment interactions.
RESULTS
Generation of the Pparg2 Pro12Ala Knockin Mouse
In order to analyze the consequences of the Pparg2 Pro12Ala
mutation in a well-defined and controllable genetic background,
this mutation was introduced into the mouse genome
(Figure 1A). Pparg2 Pro12Ala mice bred normally and transmit-
ted the variant allele to their offspring at the expected Mendelian
ratios (Figure 1B). Sequencing confirmed the presence of the
CCA / GCA mutation (Pro / Ala) at codon 12 of Pparg2
exon B without additional changes in the coding sequence
(data not shown). Using an allele-specific qRT-PCR strategy,
both Pro and Ala alleles were confirmed to express Pparg2
mRNA at equal levels in Pro/Ala adipose tissue (Table S1), prov-
ing a lack of interference by the short cloning remnants sur-
rounding exon B in the Ala allele. The expression of Pparg1
tended to be increased in epididymal white adipose tissue
(eWAT) of Ala/Ala mice (n = 9 for Pro/Pro and 13 for Ala/Ala,
+14.0%, p = 0.128), and a concomitant tendency for a decrease
inPparg2 expression (10.8%, p = 0.187) resulted in a significant
decrease in the Pparg2/1 mRNA ratio (22.0%, p = 0.00014),
which could influence the metabolic actions of PPARG (Hotta
et al., 1998; Vidal-Puig et al., 1997) (Figure 1C, upper panel). Sim-
ilar changes were seen also in gastrocnemius muscle (Figure 1C,
middle panel). In the liver, where Pparg2 is much less expressed
than in WAT, the changes inPparg2 expression and Pparg2/1 ra-
tio were even more pronounced (49.9%, p = 1.9 3 105; and
51.3%, p = 4.9 3 107; respectively) (Figure 1C, lower panel).
In line with the gene expression results, the Pro12Ala mutation
did not noticeably alter Pparg2 protein levels in WAT (Figure 1D).
Pparg2 Ala12 Improves Insulin Sensitivity and Lipid
Profiles on Chow Diet
The metabolic phenotyping of Pparg2 Pro12Ala knockin mice in
well-controlled environmental and genetic settings offers an ex-
cellent means to uncover the full extent of physiological conse-
quences of the variant. On a chow diet, Ala/Ala mice gained
less weight than Pro/Pro mice (Figure 2A) despite equal food in-
take (data not shown). Accurate body length measurement by
DEXA scan allowed reliable calculation of the BMI (Figure 2A,
inset), which was strikingly lower in 9-month-old Ala/Ala mice
(31.2 ± 0.5 versus 35.5 ± 0.7 g/cm2, p = 0.0006). DEXA scan
also revealed that not only fat mass (35%) but also lean body
mass (8%) was reduced in Ala/Ala mice (Figure 2B). Histolog-
ical analysis of eWAT as well as BAT suggested that adipocyte
size was not affected in Ala/Ala mice (Figure 2C), although the
size of individual fat pads at 12 months of age was smaller in
Ala/Ala than in Pro/Pro mice (for eWAT, 59%, p = 0.0202; sub-
cutaneous WAT, 61%, p = 0.0018; retroperitoneal WAT,
66%, p = 0.0064; and a tendency for interscapular BAT,
30%, p = 0.0726) (Figure 2D). Fittingly, cultured Ala/Ala mouse
embryonic fibroblasts (MEFs), when challenged by an adipo-
genic differentiation cocktail, contained less cells stained with
Oil red O (Figure 2E, upper panel) and had 35% lower total
triglyceride content (p = 0.0013) (Figure 2E, lower left panel). Fur-
thermore, the expression of direct Pparg target genes, such as
fatty acid binding protein 4 (Fabp4, also called aP2) and Cd36
antigen (Cd36), was reduced in differentiated Ala/Ala cells
(Figure 2E, lower right panel).
Both pharmacological and genetic analyses of PPARg func-
tion have suggested that this receptor can affect bone formation
through functional alterations in osteoblasts and osteoclasts
(Cock et al., 2004; Wan et al., 2007). DEXA scan showed a small
but significant increase in both total bone area (+5.7%, p = 0.029)
and bone mineral content (BMC) (+8.9%, p = 0.016) in Ala/Ala
mice (Figure 2F). However, bone mineral density (BMD) was
not altered. Furthermore, the Ala/Ala mice did not have spleno-
megaly (data not shown).
Biochemical analysis revealed an improved plasma lipid pro-
file in 6- to 8-week-old Ala/Ala homozygotes on chow diet
(Figure 3A, upper panel). A small decrease in total cholesterol
(Chol) and triglyceride (TG) levels was accompanied by a robust
71% decrease in the Chol content of LDL particles (p = 0.0042),
Figure 1. Floxed Pparg2 Pro12Ala Knockin
Construct and the Validation of the Result-
ing Mouse Model
(A) Construct design and recombination scheme.
Filled and open arrowheads indicate loxP and frt
sites, respectively (not to scale). Asterisk indicates
the location of Pro12Ala mutation in exon B. The
target region for the genotyping PCR is indicated.
(B) PCR genotyping over the frt and loxP sites,
showing products from wild-type (322 bp) and
knockin (480 bp) alleles from wild-type (Pro/Pro),
heterozygous (Pro/Ala), and knockin (Ala/Ala)
mice.
(C) Pparg1 (g1) and Pparg2 (g2) mRNA expression
and their ratio (g2/1) in eWAT, gastrocnemius mus-
cle, and liver of 8-week-old, chow-fed mice by
qRT-PCR, normalized to Ppib expression for
eWAT and for Ppib and 18S rRNA expression for
muscle and liver (n = 9 Pro/Pro and 13 Ala/Ala
mice). Data are presented as means ± SEM *,
p < 0.05; ***, p < 0.001 between the groups.
(D) Pparg2 protein content in Ala/Ala eWAT on
both chow and HFD, with WAT from Pparg2
knockout mice (g2/) as control. Immunoprecip-
itated (IP) total Pparg protein fraction was immu-
noblotted (IB) using a Pparg2-specific antibody.
Densitometric quantitation of the Pparg2 protein
amounts is shown above the blot.
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Figure 2. Growth, Body Composition, and Adipocyte Differentiation of Pparg2 Pro12Ala Knockin Mice on Chow
(A) Body weight development, measured periodically from 6 weeks of age. In the inset, BMI at 37 weeks of age.
(B) Total and lean body weight (left) and body fat mass (right) by DEXA scan at 37 weeks of age.
(C) eWAT (left) and BAT (right) histology as representative hematoxylin-eosin stained sections. Adipocyte sizes are indicated for eWAT of chow-fed mice (n = 4–5
per group).
(D) Fat pad weights for eWAT (left) and BAT (right).
(E) Adipocyte differentiation of MEFs, shown as representative micrographs of cells in culture (top), quantified relative triglyceride content of n = 3 replicate cul-
tures of differentiated cells (lower left), and representative effects on the mRNA expression of Pparg target genes (Fabp4 and Cd36), normalized to 18S rRNA
expression.
(F) Whole body bone area (top), BMC (middle), and BMD (bottom) by DEXA scan at 37 weeks of age. Data are presented as means ± SEM, and for (A), (B), (D), and
(F), n = 5–8 per group. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 between the Pro/Pro (P/P) and Ala/Ala (A/A) groups.
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ticles (data not shown). However, none of fasting free fatty acids
(FFAs), glucose, insulin, leptin, nor adiponectin levels differed
between Pro/Pro and Ala/Ala mice (Figure 3A). A similar metab-
olite profile also persisted in older animals (data not shown). Of
note, both liver weight and the hepatic lipid profile were un-
changed between Pro/Pro and Ala/Ala mice (data not shown).
The Ala12 allele associates with a reduced risk of T2DM by
meta-analyses and GWAS in humans (Deeb et al., 1998; Florez
et al., 2003; Ludovico et al., 2007; Saxena et al., 2007; Scott
et al., 2007; Sladek et al., 2007; Steinthorsdottir et al., 2007;
To¨njes et al., 2006; Zeggini et al., 2007). Similarly, the Ala/Ala
mice had enhanced glucose tolerance in an intraperitoneal glu-
cose tolerance test (IPGTT) (Figure 3B). Moreover, euglycemic-
hyperinsulinemic clamp showed a clear improvement in the insu-
lin sensitivity of Ala/Ala mice, as the glucose infusion rate (GIR) to
maintain their euglycemia was significantly higher than that of
Pro/Pro mice (Figure 3C). This result was confirmed in a separate
experiment (top left panel in Figure 3D), where the tissues con-
tributing to the improved insulin sensitivity of Ala/Ala mice were
determined. The basal rate of glucose appearance (Ra) or he-
patic glucose production (top middle panel in Figure 3D) as
well as glucose uptake into liver upon insulin stimulation (lower
left panel in Figure 3D) were unaltered between Pro/Pro and
Ala/Ala mice, suggesting that differences in liver glucose metab-
olism do not explain our findings. However, there was a 2-fold
increase (p = 0.0013) in glucose uptake into Ala/Ala WAT (lower
left panel in Figure 3D), suggesting a role for WAT in the improved
insulin sensitivity of Ala/Ala mice on chow. The increase in glu-90 Cell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc.cose uptake into Ala/Ala muscles did not reach statistical signif-
icance (lower panel in Figure 3D), but considering the lack of any
difference in the liver and the relatively small overall contribution
of WAT to the whole body glucose utilization, contribution from
skeletal muscle to the improved GIR and glucose disappearance
rate of Ala/Ala mice cannot be completely excluded (top panel in
Figure 3D). The observed changes in glucose uptake in Ala/Ala
WAT and muscle were not associated, however, with altered
basal Glut4 protein or mRNA expression (data not shown). Glu-
cose uptake by the heart and brain were unchanged between
Pro/Pro and Ala/Ala mice.
Environmental and especially nutritional factors modulate the
phenotypic effects of the Pro12Ala variant in humans (Luan
et al., 2001; Memisoglu et al., 2003). To uncover any differences
in how Pro/Pro and Ala/Ala mice metabolize lipids versus carbo-
hydrates for energy, we measured their energy expenditure by
indirect calorimetry. However, respiratory exchange ratio (RER)
did not differ between Pro/Pro and Ala/Ala mice on chow (top
panel in Figure 3E). Simultaneous measurement of spontaneous
locomotor activity showed that Ala/Ala mice were more active
during the onset of the dark period (bottom panel in Figure 3E)
and, perhaps consequently, produced more heat and consumed
more water, but without altering food intake (Figure S2).
Finally, blood pressure did not differ between Pro/Pro and
Ala/Ala mice (99.1 ± 2.5 versus 102 ± 1.4 mmHg, p = NS).
Pparg2 Ala12 Improves Longevity
The Ala12 variant of Pparg2 has been suggested to increase lon-
gevity in humans (Barbieri et al., 2004). Since the reduction in fat
mass of Ala/Ala mice was similar to what occurs during caloric
restriction and subsequent lifespan extension (Bordone and
Guarente, 2005), and in view of the improved metabolic profile,
we hypothesized that the variant might have a beneficial effect
on lifespan. The Ala/Ala mice indeed lived on average 13%
longer on chow than their Pro/Pro littermates (109.6 ± 0.35 ver-
sus 123.9 ± 0.97 weeks, p = 0.002) (Figure 4). This result confirms
the previous, suggestive results on humans (Barbieri et al., 2004)
and demonstrates how the beneficial metabolic effects of the Ala
variant project onto the lifelong survival of the organism.
Metabolic Benefits of the Pparg2 Ala12 Allele
Are Eliminated upon High-Fat Feeding
The consequences of the Pro12Ala mutation on obesity in hu-
man populations (Ek et al., 1999; Masud and Ye, 2003) prompted
us to challenge our Pro12Ala knockin mice with high-fat feeding.
Figure 3. PlasmaMetabolite Profile, Insulin Sensitivity, Glucose Utilization, Respiratory Exchange Ratio, and Total Spontaneous Locomotor
Activity of Pparg2 Pro12Ala Mice on Chow
(A) Plasma concentrations for triglycerides (TG), FFAs, total cholesterol (Chol), HDL and LDL cholesterol (upper); and glucose (Glc, mmol/L), insulin (Ins, mg/L),
leptin, and adiponectin (lower) (n = 9–16).
(B) Glucose tolerance by IPGTT. The inset shows the area under the glucose curve above baseline (AUC) (n = 6–7).
(C) Insulin sensitivity by euglycemic-hyperinsulinaemic clamp, shown as GIRs (mg/kg*min1) over the whole test duration, and in the inset, averaged over the
clamped period, i.e., the last 60 min (n = 7).
(D) Whole body and tissue-specific glucose utilization by euglycemic-hyperinsulinaemic clamp with radiolabeled glucose and 2-deoxyglucose tracers. The top
panel shows, in mg/kg*min1, GIRs, basal rates of glucose appearance (Ra, i.e., hepatic glucose production), and insulin-stimulated rates of glucose disappear-
ance (Rd) (n = 4–6). The bottom panel shows, in ng glucose/mg tissue*min1, insulin-stimulated glucose uptake into liver and WAT (left graph) and into quadriceps
(Qua), gastrocnemius (Gas) and soleus (Sol) muscles, heart, and brain (right graph).
(E) RER (top) and total spontaneous locomotor activity (bottom) (n = 6–8). Statistically significant differences are shown only for two or more consecutive points.
Data are presented as means ± SEM *, p < 0.05; **, p < 0.01 between the Pro/Pro (P/P) and Ala/Ala (A/A) groups.
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(HFD) appeared somewhat more obese than Pro/Pro mice (Fig-
ure 5A). For example, BMI (48.0 ± 3.8 versus 40.1 ± 0.8 g/cm2,
p = 0.125), body weight (at 16 weeks of diet, 39.2 ± 1.98 versus
35.0 ± 0.50 g, p = 0.086), and fat mass (14.6 ± 3.8 versus 10.7 ±
1.5 g, p = 0.359) of Ala/Ala mice tended to exceed that of Pro/Pro
mice. Although the differences were not statistically significant,
the analysis of chow and HFD data together demonstrated
a clear, statistically significant interaction for Pro12Ala genotype
and diet on BMI (p = 0.002) and body weight (at 16 weeks of diet,
p = 0.017). Fasting plasma glucose or lipid parameters, again in
contrast to chow, did not differ between Pro/Pro and Ala/Ala
mice on HFD (data not shown). The diet-dependent differences
in the Pro12Ala phenotype were also evident at the level of whole
body glucose homeostasis, as both IPGTT (Figure 5B) and eugly-
cemic-hyperinsulinemic clamp (Figure 5C) demonstrated the
loss of protective effect by the Ala/Ala genotype on HFD. Fur-
thermore, the differences seen on chow in spontaneous activity
and heat production were all eliminated on HFD (Figures 5D and
S2). Collectively, the greatly increased difference in the adiposity
and glucose tolerance of Ala/Ala mice when compared to Pro/
Pro mice between the chow and high-fat-fed states (Figure 5E)
reveals a diet-dependent metabolic response for the Pro12Ala
variant of Pparg2.
Since Pparg agonists, like pioglitazone, are widely used insulin
sensitizers in the treatment of T2DM, we treated Pparg2 Pro/Pro
and Ala/Ala mice either with HFD or HFD + 0.004% pioglitazone
for 5 weeks (Rocchi et al., 2001). The Ala/Ala mice again showed
a tendency for increased weight gain (1.10 ± 0.07 versus 0.90 ±
0.07 g/day, p = 0.161), an effect that seemed to be accentuated
in Ala/Ala mice on HFD + pioglitazone (1.20 ± 0.09 versus 0.88 ±
0.12 g/day, p = 0.072). However, food intake or insulin sensitivity
did not differ between the genotypes (data not shown). Thus,
upon caloric excess in mice, Pro12Ala variant appears to modu-
late pioglitazone effects only mildly.
Pparg2 Pro12Ala Alters Transcriptional Regulation
in Muscle and WAT
To capture the transcriptional effects of the Ala12 mutant isoform
of Pparg2 that potentially underlie the phenotypic changes
Figure 4. Longevity of Pparg2 Pro12Ala Mice on Chow
Data are presented as cumulative survival curves. **, p < 0.01 between the Pro/
Pro (solid line, n = 58) and Ala/Ala (hatched line, n = 25) groups.
92 Cell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc.observed, we performed gene expression microarray analysis
of eWAT, gastrocnemius muscle, and liver of 23-week-old males
on either chow or 15 weeks HFD (N = 8–10 per group, 112 micro-
arrays in total). Based on the molecular mechanisms through
which the Pro12Ala point mutation affects Pparg action, we ex-
pected to find only moderate changes, especially in comparison
to the more dramatic changes seen in many Pparg gene knock-
out models (Koutnikova et al., 2003). Indeed, on chow, the ex-
pression of only two, six, and one genes, respectively, were
altered in Ala/Ala WAT, muscle, and liver, and all by less than
25% (Figure 6A and Table S2). On HFD, more changes were ob-
served in both WAT (46 genes) and muscle (95 genes), although
none in the liver, and again the magnitude of change was below
25% (Figure 6A and Table S2).
Considering that the existing evidence points to a reduced
transcriptional activity of the Ala12 mutant, and that WAT is the
tissue expressing Pparg2 at the highest level, it is not surprising
that in WAT, most genes with changes were downregulated in
Ala/Ala mice (76% on HFD, Figure 6A). In contrast, a great major-
ity of genes with altered expression were upregulated in Ala/Ala
muscle (86% in both chow and HFD, Figure 6A). One explana-
tion for this apparent discrepancy could be that in a tissue like
muscle, expressing only low levels of Pparg2, altered signaling
from other tissues such as WAT could take precedence.
The most consistent change observed was the upregulation of
adiponectin receptor 2 (Adipor2) expression in Ala/Ala WAT and
muscle on both chow and HFD (Figure 6A and Table S2). Inter-
estingly, adiponectin (Adipoq) expression itself was upregulated
in Ala/Ala muscle on HFD. Adipoq was also upregulated in the
muscle of 8-week-old, chow-fed Ala/Ala mice in an independent
analysis by qRT-PCR (data not shown). These observations sug-
gest that adiponectin signaling likely plays a role in the pheno-
typic effects seen in Pparg2 Pro12Ala mice.
Due to the low number of Pro12Ala-associated changes, we
opted to use Gene Set Enrichment Analysis (GSEA) that detects
significantly coregulated sets of genes even when the individual
genes do not contribute significantly (Mootha et al., 2003; Subra-
manian et al., 2005). In addition to the gene sets contained in the
KEGG and GenMAPP repositories, we also analyzed smaller
groups of gene sets for focused subject areas, selected from
the Molecular Signatures Database (http://www.broad.mit.edu/
gsea/msigdb). GSEA demonstrates a considerable concentra-
tion of enrichment in gene sets containing genes upregulated
in the muscle of HFD-fed Ala/Ala mice (Figure S3 and Tables
S3 and S4), suggesting a role for muscle in the Pro12Ala pheno-
type. The focused approach provided evidence that such signal-
ing molecules as leptin and other adipocytokines (e.g., adipo-
nectin); mTor, Chrebp, and insulin (‘Signaling’ subset); and
Ppars in general (‘Ppar and thiazolidinedione effects’ subset)
are associated to the loss of protective effects of the Ala allele
upon caloric excess (Table S4). In the muscle of high-fat-fed
mice, Pro12Ala may also target fatty acid metabolism and genes
that become upregulated in obesity (‘Metabolism, diabetes, and
obesity’ subset, Table S4). Surprisingly, however, only G protein-
related gene sets had significant enrichment in WAT (Figure S3
and Tables S3 and S4). Together with the observation that nearly
all enrichments in the liver were also found in G protein-related
gene sets, this suggests a previously poorly described connec-
tion between the Pparg2 Pro12Ala variant and G protein function.
Figure 5. Body Weight Development, Insulin Sensitivity, Respiratory Exchange Ratio, and Spontaneous Locomotor Activity of Pparg2
Pro12Ala Knockin Mice on High-Fat Diet
(A) Body weight development, measured periodically from 6 weeks of age. The weight curves on chow from Figure 3A are shown for comparison in gray.
(B) Glucose tolerance by IPGTT, conducted after 6 months of high-fat feeding. The inset shows the AUC.
(C) Insulin sensitivity by euglycemic-hyperinsulinaemic clamp, shown as GIRs (mg/kg*min1) over the whole test duration and, in the inset, averaged over the
clamped period, i.e., the last 60 min. The corresponding data on chow from Figure 4C are provided for comparison in gray.
(D) RER (top) and total spontaneous locomotor activity (bottom) (n = 6–8; same mice as in Figure 3E, but after 8 weeks of HFD). Statistically significant differences
in two or more consecutive points were not observed.
(E) The diet-dependent effect of the Pro12Ala variant on adiposity and glucose tolerance, visualized by a scatter plot of mean fat mass against the mean AUC for
indicated groups. Data are presented as means ± SEM, and n = 4–8 mice per group. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 between the indicated groups of
Pro/Pro (P/P) and Ala/Ala (A/A) mice on chow and HFDs.
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the phenotype of the Pro12Ala mutant, we plotted Pearson cor-
relates to both plasma adiponectin levels and Pparg2 gene ex-
pression for all expressed genes to generate ‘cocorrelation’
graphs (Figure 6B). The ball-like distributions of R2 values in
Pro/Pro WAT on both diets showed that very few genes cocorre-
late strongly with adiponectin levels and Pparg2 expression (top
panel in Figure 6B, graphs in blue). However, in Ala/Ala WAT, the
shapes of R2 distributions were elongated on both diets, and
moreover, the Ala/Ala distributions were in opposite orientations
on chow and HFD (top panel in Figure 6B, graphs in red). The ef-
fect of dietary status was limited to Ala/Ala mice also in muscle,
where HFD considerably tightened the Ala/Ala cocorrelation dis-
tribution (bottom panel in Figure 6B). Collectively, this suggests,at the level of transcriptional regulation, that the Pro12Ala variant
sensitizes Pparg2 to adiponectin signaling, and that the dietary
status affects this sensitization.
Altered Cofactor Recruitment by PPARg2
Pro12Ala Variant
The gene expression changes suggested that the interaction of
Pro12 and Ala12 forms of PPARg2 with other transcriptional
coregulators might be altered. We hence used GST pull-down
assays to analyze the capacity of Pro12 and Ala12 isoforms of
PPARg2 to interact with a representative set of established
PPARg coregulators in the absence and presence of the PPARg
ligand rosiglitazone (Rosi). Both the ligand-independent and the
ligand-dependent interactions with the coactivators MED1 (alsoCell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc. 93
Figure 6. The Impact of Pparg2 Pro12Ala Variant on Gene Expression Patterns
(A) Hierarchical clustering of altered genes in eWAT (top), gastrocnemius muscle (bottom), and liver (boxed inset in the top) on chow and HFD. The data represent
log2 ratios to a virtual pool of high-fat-fed Pro/Pro groups for each tissue. White and black bars to the right of each cluster indicate the location of Pro/Pro and
Ala/Ala samples within the clusters, respectively.
(B) Cocorrelations for expressed genes against plasma adiponectin (y axis) and Pparg2 gene expression (x axis) in eWAT (top) and gastrocnemius muscle (bot-
tom) on chow and HFD. Each dot in the graphs represents Pearson R2 values for the two parameters. Intensity of the color (blue, Pro/Pro; red, Ala/Ala) corre-
sponds to the number of genes with similar cocorrelations.
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Figure 7. The Impact of the Pparg2 Pro12Ala Variant on Cofactor Recruitment In Vitro
The effect of the Pro12Ala variant of Pparg2 on cofactor recruitment by in vitro GST pull-down assay for select Pparg cofactors using Pro12 or Ala12 PPARg2
variants. Data are presented as the relative amount of PPARg2 pulled down by the indicated cofactors in the absence () or presence (+) of synthetic PPARg
ligand Rosi from three independent experiments. Cofactors interacting strongly with PPARg2 are shown on the left, with representative, short exposure blots
on top displaying the fold induction of interaction upon ligand (Rosi) treatment. The cofactors with weaker interaction, requiring longer exposure, are shown
on the right. The insets on the left in each panel show the corresponding exposures of 1% input. Data are presented as means ± SEM.
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iants of PPARg2 (Figure 7). However, the interaction of corepres-
sor Ncor was strongly reduced with both the unliganded and
liganded Ala12 mutant, although it appeared to have the
capacity to release Ncor upon ligand binding similar to that of
the Pro12 variant. In contrast, the basal interaction with Pgc1a
and the p160 coactivator SRC-1 (and perhaps also SRC-2)
was robustly decreased in the Ala12 mutant, and their ligand-de-
pendent recruitment was totally abolished. These experiments
demonstrate that the Pro12Ala mutation selectively alters the
profile of coregulator recruitment. Furthermore, the ligand de-
pendency of PPARg2 action is also selectively altered, but in
a subset of coregulators that at least partly differs from that in
which interaction per se is altered.
DISCUSSION
In lean humans, the Ala12 allele of PPARG2 has been associated
with reduced risk of obesity (Altshuler et al., 2000; Deeb et al.,
1998). On the other hand, Ala12 becomes the risk allele for fur-
ther weight gain in obese patients (Ek et al., 1999; Masud and
Ye, 2003). Correspondingly, the Ala12 allele is viewed as protec-
tive against T2DM in nonobese subjects (Altshuler et al., 2000;
Deeb et al., 1998), whereas in obese subjects the effect is less
clear (Ek et al., 1999). The phenotype of our Pro12Ala knockin
mice essentially replicates these observations, as Ala/Ala ani-
mals were leaner and more insulin sensitive than Pro/Pro animals
but had a tendency for increased weight gain and lost the bene-
fits on insulin sensitivity upon high-fat feeding. Adipose tissue
contributes to the improved insulin sensitivity of the Ala/Ala
mice on chow, although a mild effect from skeletal muscle ap-
pears also likely. Indeed, it is possible that the high insulin
dose (18 mU/kg/min) used in our clamp experiment had began
to saturate the signaling for insulin-dependent glucose uptake,
especially in the rather insulin-sensitive skeletal muscle, thus
masking any small differences (Chibalin et al., 2008). Since the
relative lipodystrophy of the mice deficient in Pparg activity per-
sists also on HFD (Jones et al., 2005; Kubota et al., 1999;Medina-Gomez et al., 2007), the increased responsiveness to
HFD of Ala/Ala mice implies that in the presence of a positive en-
ergy balance, the adipogenic capacity of the Ala12 variant ex-
ceeds that of the Pro12 variant, in contrast to the apparently
lower activity of the Ala12 variant on chow. Consistent with the
reduced fat mass in vivo, the Ala/Ala genotype affected adipo-
cyte maturation as well in vitro. These results collectively suggest
that the Pro12Ala variant is a critical, diet-dependent metabolic
sensor that, especially in the adipose tissue, modulates the effi-
cacy of Pparg2 in the control of gene-environment interaction.
TZDs like pioglitazone, however, appear not to strongly interact
with the Pro12Ala genotype upon caloric excess.
The diet-dependent impact of the Pro12Ala variant also af-
fected circulating lipids as the improved profile in Ala/Ala mice
on chow diet was obliterated on HFD. The Ala12 variant seems
therefore to be beneficial to lipid homeostasis, at least when die-
tary fat is not in excess. Since elevated levels of triglycerides are
a risk factor for the development of insulin resistance (Laakso,
2004), it is possible that in the chow-fed Pro12Ala mice, improved
insulin sensitivity and lower lipid levels are causally connected.
Although the Pro12Ala variant improved lipid profiles and insu-
lin sensitivity in lean mice, it did not affect energy metabolism at
large, since RER did not differ between Pro/Pro and Ala/Ala mice
on either chow or HFD. Also, thermogenesis in the high-fat-fed
state was unaltered (data not shown). However, since the diet-
dependent increase in the spontaneous activity of Ala/Ala mice
on chow was limited to the onset of the dark period, it is intriguing
to speculate whether Pro12Ala might affect behavior or some
other brain-related function. Finally, the modest bone phenotype
of Ala/Ala mice, reflected by an increase in bone area and min-
eral content in the wake of a constant mineral density, again
highlighted the links between adipocytes and osteoblasts
(Cock et al., 2004) and Pparg and osteoclasts (Wan et al.,
2007), which thus remain pertinent.
The increased longevity of our Pparg2 Ala/Ala mice fully sup-
ports the earlier suggestion that humans carrying the Ala12 var-
iant may have longer lifespans (Barbieri et al., 2004). Although
the extended survival of Ala/Ala mice was not independent ofCell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc. 95
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sitivity, these results nevertheless propose a role for Pparg2 in
longevity determination. Due to the high prevalence (80%–
100%) in human populations of the more active Pro12 allele,
the shorter lifespan of the Pparg2 Pro/Pro mice requires addi-
tional scrutiny in humans. Our data in fact suggest that the
Ala12 isoform of Pparg2 may functionally mimic the caloric re-
stricted state, hence resulting in improved longevity. There re-
sults warrant also further analysis of the effects of Pparg agonists
on longevity.
From a mechanistic point of view, it is interesting to stress that
the Pro12Ala mutation resides within the 30 N-terminal amino
acids of the activation function 1 domain (AF1) that are unique
to Pparg2 (Fajas et al., 1997; Tontonoz et al., 1994a). This region
confers the increased transcriptional capacity and adipogenic
potential of Pparg2 compared to Pparg1 (Ren et al., 2002; Wer-
man et al., 1997). We show here that the Pro12Ala mutation alters
both ligand-dependent and ligand-independent interaction be-
tween PPARg2 and its cofactors, like Pgc1a, SRC1, and Ncor,
thus expanding the molecular basis for the Pro12Ala effects be-
yond decreased DNA binding efficiency (Deeb et al., 1998).
Since transcriptional coregulators modulate metabolic homeo-
stasis (Feige and Auwerx, 2007), it is likely that the selective re-
cruitment of coregulators by the PPARg2 Pro12Ala mutant
mechanistically contributes to the metabolic phenotype of Ala/
Ala mice. However, the exact contribution of the interaction
with PPARg2 versus other transcription factors to the in vivo
function of individual coregulators remains elusive. Conse-
quently, it is difficult to precisely link the results of the in vitro in-
teraction assays with the phenotype of our mouse model.
Our gene expression results, including the consistent overex-
pression of Adipor2 in Ala/Ala WAT and muscle and the modula-
tion of cocorrelation patterns of plasma adiponectin and Pparg2
by diet only in Ala/Ala WAT and muscle, suggest that the Ala12
mutant sensitizes the transcriptional activity of Pparg2 in WAT
and muscle to adiponectin signaling, especially when conveyed
through Adipor2. It is thus plausible that altered adiponectin sig-
naling contributes to the improvement of insulin sensitivity of
lean Ala/Ala mice, as this adipocytokine is an insulin sensitizer
(Kubota et al., 2002). Interestingly, increased adiponectin levels
have been reported in Ala/Ala humans (Mousavinasab et al.,
2005). The surprising finding that the expression of G protein-
coupled receptors (Gpcrs) is affected by the Pro12Ala variant
in WAT and liver may also have a link to adiponectin signaling,
since sequence analysis has shown that adiponectin receptors
are distantly related to Gpcrs (Yamauchi et al., 2003). The con-
siderable differences in gene expression changes associating
to the Pro12Ala variant between the two diets support the hy-
pothesis that the Pro12Ala phenotype depends on nutritional
status and thereby underscore that Pparg2 functions as an envi-
ronmental sensor.
Collectively, our results establish the diet-dependent influence
of Pparg2 Pro12Ala variant on metabolic control via modulated
cofactor interaction and changes in gene expression patterns
in mice. These data hence consolidate Pparg2 as an important
factor at the interface between genes and the environment and
may provide avenues to better, possibly Pro12Ala genotype-de-
pendent, treatment strategies for insulin resistance in T2DM and
the metabolic syndrome.96 Cell Metabolism 9, 88–98, January 7, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animal Experiments
Generation of Pparg Pro12Ala mutant mice on a hybrid C57BL/6J/129 SV
background has been described previously (Koutnikova et al., 2003). We ana-
lyzed congenic mice backcrossed onto C57Bl/6 genetic background for at
least nine generations. Genotyping was performed by PCR, using standard
conditions and primers HA24 (50-GTGAATTAGCTTCCTCTC-30) and HA26
(50-GTGAAGCAAATCTGAATAG-30 ) that produce 322 and 480 bp products
from the Pro and Ala alleles, respectively. Pparg Pro12Ala and wild-type litter-
mates were fed regular rodent chow or HFD (D12330, 5560 kcal/kg; Research
Diets; New Brunswick, NJ), as indicated. Only males were used, to minimize
possible effects of variation in estrus status of females. Since the body weight
development of Pro/Ala heterozygote mice was intermediate to that of Pro/Pro
and Ala/Ala mice, we focused on the two homozygote genotypes in further
experimentation. Mice were housed with a 12 hr light-dark cycle and had
free access to water and food.
The phenotyping protocols included the following: (1) blood collection at fed
or after 4 hr or overnight fast state, as indicated; (2) body composition by
DEXA; (3) systolic arterial blood pressure by tail-cuff system; (4) glucose toler-
ance by IPGTT (16 hr fasted, 2 g glucose/kg mouse); (5) insulin sensitivity, ei-
ther by euglycemic-hyperinsulinemic clamp (4 hr fast, 18 mU insulin/kg/min,
clamped at 5.5 mmol/L for 60 min) or by adding to that a continuous infusion
of 0.1 mCi/min D-[3-3H]-glucose (Perkin Elmer) to measure basal and insulin-
stimulated glucose turnover, and a 3 mCi bolus of 2-Deoxy-D-glucose-1-14C
(Sigma-Aldrich) to measure tissue glucose uptake; (6) cold test; and (7) 25 hr
monitoring with integrated indirect calorimetry and measurements for sponta-
neous activity as well as food and water intake (TSE LabMaster system; Bad
Homburg, Germany). These tests were performed as outlined at the EMPReSS
website (http://empress.har.mrc.ac.uk) and as described (Chibalin et al., 2008;
Lagouge et al., 2006). Tissue collection and clinical biochemistry was per-
formed as described (Koutnikova et al., 2003). LDL cholesterol was calculated
as the difference between total and HDL cholesterol or analyzed using a fast
lipoprotein liquid chromatography method (Ma¨rz et al., 1993). Unless specified
otherwise, n = 5–8 mice per group were used in all in vivo experiments.
Survival cohort consisted of 57 Pro/Pro and 25 Ala/Ala mice. Deaths were
recorded weekly. Mice observed as moribund were euthanized and recorded
as dead on that week. All Pro/Pro mice reached the endpoint, but a few Ala/Ala
mice survived at the time of analysis.
Molecular Methods
RNA was isolated using the TRIzol Reagent (Invitrogen; Carslbad, CA) or
RNeasy Mini or Lipid Tissue Mini kits (QIAGEN; Hilden, Germany). Synthesis
of cDNA was performed using the SuperScript II System (Invitrogen) and ran-
dom hexamer primers. Quantitative RT-PCR was performed by using Quanti-
Tect SYBR Green PCR Kit from QIAGEN according to the manufacturer’s pro-
tocols. As the invariant control, 18S rRNA or peptidylprolyl isomerase B (Ppib,
also calledCyclophilin B) mRNA or both was used. Primer sequences are avail-
able at http://www-igbmc.u-strasbg.fr/recherche/Dep_NG/Eq_JAuwe/Publi/
Paper.html.
Nuclear protein extraction, immunoprecipitation, and immunoblotting were
performed as described (Lagouge et al., 2006), using Pparg antibodies from
Santa Cruz.
GST pull-down experiments were performed as described (Feige et al.,
2007). The coregulator interacting domains fused to GST were expressed in
E. coli from plasmids as described (Feige et al., 2007; Rocchi et al., 2001)
and purified on a glutathione affinity matrix (Pharmacia). Human PPARg2
Pro12 and Ala12 isoforms were produced in reticulocyte lysates (Promega)
in the presence of 35S-Methionine, and the amounts of receptor were equal-
ized to normalize for differences in production efficiency.
Adipocyte Differentiation
MEFs from Pparg2 Pro/Pro and Ala/Ala embryos were differentiated to adipo-
cytes and further analyzed as described (Fajas et al., 2002).
Gene Expression Profiling
Eight-week-old male Pro/Pro and Ala/Ala littermate mice were fed either reg-
ular rodent chow or HFD (as above) for 15 weeks (n = 8–10 per group), at which
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amplification, labeling, and microarray (Genechip Mouse Genome 430 2.0
Array; Affymetrix, Inc.; Santa Clara, CA) processing steps were performed
by the Rosetta Inpharmatics Gene Expression Laboratory (Seattle, WA) using
custom automated procedures, in compliance with manufacturer protocols.
Data Analysis
For computation of the statistics from the mouse data, SPSS version 14 for
Windows (Chicago, IL) was used. Data are presented as means ± SEM.
None of the variables significantly deviated from normal distribution (One-
Sample Kolmogorov-Smirnov Test). Two-tailed Student’s t test was used for
comparing means. Survival was tested using Kaplan-Meier statistics. Full fac-
torial univariate linear modeling was used to analyze the effect of several fac-
tors. For correlation analysis, Pearson correlation was used. Microarray data
were processed using Rosetta Resolver (Rosetta Inpharmatics; Seattle, WA)
and expressed as relative to the virtual pool of Pro/Pro mice fed with an
HFD (mlratio). Gene expression signatures were generated from these mlratios
for expressed genes (25% of RMA processed intensities above 60% quantile)
by t testing (Pro/Pro versus Ala/Ala) and correcting for multiple testing (20%
cutoff for False Discovery Rate). GSEA was performed according to provider
suggestions, Pro/Pro versus Ala/Ala. Statistical significance was declared if
p < 0.05.
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